NASDAQ:IMDZ - Immune Design Corp.
$1.42
 $-0.04
-2.74%
1:30PM EDT
2019-02-15
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer. The Company is engaged in developing multiple product candidates from its two discovery platforms, ZVex and GLAAS. Its primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase I and Phase II trials. CMB305 is targeting the NY-ESO-1 tumor antigen, in which a priming agent called LV305 from its ZVex platform is dosed sequentially with an agent from its GLAAS platform. G100 leverages the range of endogenous antigens found in the tumor microenvironment, including neoantigens. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  IMDZ     avg for
industry  
  avg for
sector  
42 stocks weight:  46. 86   0. 00   0. 00  
42 stocks rank:  2. 84 K 1. 86 K 1. 09 K
# analyst opinions:  4. 00   14. 92   14. 43  
mean recommendation:  2. 20   1. 91   1. 93  

quick ratio:  12. 63   5. 37   1. 81  
current ratio:  13. 11   5. 69   2. 19  

target price low:  2. 00   88. 97   117. 82  
target price avg:  2. 86   115. 19   141. 96  
target price high:  4. 13   143. 40   163. 16  
1-yr high:  4. 95   124. 30   142. 77  
last close:  1. 46   101. 85   127. 84  
50-day avg:  1. 51   98. 27   122. 46  
200-day avg:  2. 87   99. 72   122. 70  
1-yr low:  1. 15   78. 19   100. 16  
volume:  89. 90 K 2. 38 M 4. 64 M
50-day avg volume:  374. 18 K 3. 31 M 4. 94 M
200-day avg volume:  363. 99 K 3. 23 M 4. 28 M

1-day return:  -2. 01 % 0. 22 % 0. 48 %
this week return:  0. 00 % 1. 77 % 2. 01 %
12-wk return:  3. 55 % 6. 56 % 3. 33 %
52-wk return:  -52. 92 % -2. 23 % 14. 35 %

enterprise value (EV):  -37. 07 M 55. 17 B 104. 51 B
market cap:  70. 33 M 49. 01 B 96. 46 B
EBITDA:  -55. 60 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 67   -91. 79   2. 29  
enterprise/revenue (EV/R):  -16. 81   29. 84   23. 39  
total revenue:  2. 21 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -53. 14 M 2. 37 B 3. 58 B

shares outstanding:  48. 16 M 607. 99 M 1. 22 B
shares:  22. 54 M 605. 53 M 1. 15 B
shares short:  722. 28 K 11. 62 M 12. 55 M
shares short prior month:  923. 95 K 11. 95 M 13. 44 M
short ratio:  2. 24   4. 82   3. 10  
short % of float:  2. 05 % 6. 19 % 2. 82 %
total cash/share:  2. 23   12. 02   11. 46  
total cash:  107. 39 M 7. 41 B 7. 37 B
free cash flow:  -26. 12 M 95. 99 M 2. 04 B
operating cash flow:  -56. 31 M 164. 74 M 3. 04 B

book value:  2. 17   14. 43   28. 26  
price/book:  0. 67   -1. 57   -2. 97  
gross profits:  -36. 56 M 8. 28 B 18. 09 B
operating margins:  -2538. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  -33. 69 % --- ---
1-yr mean volatility:  -0. 19 % 0. 01 % 0. 06 %

1-yr EPS:  -1. 14   3. 03   4. 09  
forward EPS:  -1. 10   4. 33   6. 99  
P/E:  -1. 28   6. 11   26. 91  
forward P/E:  -1. 37   8. 38   10. 48  
PE/G:  0. 12   0. 37   5. 61  
growth:  -10. 50 % 683. 72 % 104. 79 %
earnings high:  -0. 25   1. 27   1. 66  
earnings avg:  -0. 29   1. 01   1. 53  
earnings low:  -0. 33   0. 76   1. 40  
revenue high:  4. 00 M 2. 86 B 11. 19 B
revenue avg:  1. 10 M 2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -36. 58 % -3. 27 % 3. 81 %
return on equity:  -63. 61 % 107. 48 % 27. 82 %
revenue growth:  -10. 50 % 648. 36 % 97. 70 %
revenue/share:  0. 05   14. 68   59. 83  

beta (1yr vs S&P500):  1. 13   1. 21   0. 93  
sharpe (1yr):  -0. 62   0. 06   0. 98  

held % insiders:  1. 34 % 6. 46 % 3. 21 %
held % institutions:  85. 64 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : IMDZ
.    + 0.067 =         0.067 :: INITIAL WEIGHT
.  + 475.236 =       475.303 :: inverse volume-to-price addition
.  + 337.573 =       812.876 :: spline projection addition
.  - 182.089 =       630.787 :: poor performance penalty
.     x 0.66 =       416.071 :: one-year gains+dividend factor
.    x 4.864 =      2023.743 :: 13 weeks' performance factor
.    x 1.492 =      3020.413 :: industry recommendation factor
.    x 1.887 =      5698.302 :: symbol recommendation factor
.    x 0.996 =       5677.46 :: return on assets factor
.    x 0.994 =      5641.348 :: return on equity factor
.    x 0.999 =      5635.424 :: revenue growth factor
.    x 2.302 =     12972.165 :: current ratio factor
.    x 1.042 =     13518.323 :: quick ratio factor
.    x 1.203 =     16258.157 :: short ratio factor
.    x 2.007 =       32625.7 :: price-to-book factor
.    x 5.583 =    182140.887 :: EBITDA multiple factor
.    x 2.169 =    395104.834 :: P/E weight
.    x 1.693 =    668717.771 :: PE/G factor
.    x 1.498 =   1002017.703 :: beta factor
.     x 0.62 =    620968.561 :: sharpe factor
.    x 1.643 =   1020435.508 :: target low factor
.    x 1.327 =   1354087.271 :: target mean factor
.    x 1.135 =   1537203.088 :: target high factor
.    x 1.066 =   1638063.297 :: industry 12-weeks return
.    x 0.989 =   1620575.313 :: "drift" penalty 2 days ago
.      x 1.0 =   1620267.422 :: overall "drift" factor
.    x 0.998 =   1617774.744 :: largest single-day jump factor
.    x 0.064 =    102911.879 :: low price factor
.      x 1.0 =    102918.787 :: factor hist industry gain for week 06
.   cubeRoot =        46.863 :: reduced for readability
.                     46.863 :: FINAL WEIGHT for NASDAQ:IMDZ


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org